Abstract 14707: Synergistic Cardiovascular Benefits of Combined GLP-1 Receptor Agonists and SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy in Patients with Type 2 Diabetes and HFpEF
Background: Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular benefits in type 2 diabetes (T2D). While SGLT2i is a cornerstone therapy for heart failure with preserved ejection fraction (HFpEF), the incremental prognostic benefit of...